Table of Contents Author Guidelines Submit a Manuscript
Pathology Research International
Volume 2011 (2011), Article ID 932932, 6 pages
Review Article

EGFR Signaling in Colorectal Carcinoma

Department of Pathology, University of Pittsburgh Medical Center, Presbyterian Hospital, A610, 200 Lothrop Street, Pittsburgh, PA 15213-2546, USA

Received 18 October 2010; Accepted 5 January 2011

Academic Editor: Rhonda K. Yantiss

Copyright © 2011 Alyssa M. Krasinskas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The epidermal growth factor receptor (EGFR) and its downstream signaling pathways are involved in the development and progression of several human tumors, including colorectal cancer. Much attention has been given to the EGFR pathway as of lately because both EGFR and some downstream components serve as targets for anticancer therapy. In addition to playing a critical role in targeted therapy, alterations in this pathway can have prognostic implications. The EGFR pathway and its impact on colorectal carcinogenesis and prognosis are the emphasis of this paper. Since prognosis is tightly related to response to various therapies, the predictive value of the components of this pathway will be briefly discussed, but this is not the focus of this paper.